PDE2A

PDE2A is a dual-substrate cyclic nucleotide phosphodiesterase that hydrolyzes both cAMP and cGMP, with its catalytic activity allosterically stimulated by cGMP binding to its GAF-B domain, enabling it to function as a molecular switch that couples cGMP signals to cAMP degradation in neurons, cardiomyocytes, and endothelial cells (PMID:15938621, PMID:29392776, PMID:26178667). The PDE2A3 splice variant is targeted to synaptic membranes through sequential N-terminal myristoylation at Gly2 and palmitoylation at Cys5, and PDE2A acts presynaptically in hippocampal and striatal circuits to regulate cAMP/PKA signaling downstream of NO/cGMP inputs (PMID:19632989, PMID:26178667, PMID:40412662). PDE2A knockout in mice causes embryonic lethality due to hepatoblast apoptosis driven by cAMP/ICER-mediated Bcl2 downregulation, and haploinsufficiency produces disproportionate cGMP elevation with compensatory nNOS upregulation in striatum (PMID:32326334, PMID:39733958). A homozygous loss-of-function missense mutation (p.Asp480Gly) in the GAF-B domain causes early-onset hereditary chorea, establishing PDE2A as essential for normal striatal function (PMID:29392776).

1. 1999 Medium

   Establishing where PDE2A protein is expressed at the cellular level resolved that it is selectively present in venous/capillary but not arterial endothelium, implying a tissue-specific role in cyclic nucleotide signaling at vascular barriers.

   Evidence Immunocytochemistry and in situ hybridization in cardiac and renal tissue sections

   PMID:10375378

   Open questions at the time

   • No functional consequence of endothelial expression was demonstrated
   • Neuronal versus endothelial relative contributions to whole-organ PDE2A activity were not assessed
2. 2005 High

   Solving the crystal structure of the PDE2A catalytic domain at 1.7 Å identified active-site residues (Asp811, Gln812, Ile826, Tyr827) that determine substrate and inhibitor selectivity, providing the first atomic-level explanation for PDE2A's dual cAMP/cGMP hydrolysis and a framework for selective inhibitor design.

   Evidence X-ray crystallography of catalytic domain plus mutagenesis with enzymatic activity assays using wheat germ in vitro translation

   PMID:15938621

   Open questions at the time

   • Full-length structure including GAF domains was not resolved
   • Structural basis of cGMP-mediated allosteric activation remained unknown
3. 2009 High

   Determining how PDE2A reaches synaptic membranes revealed a two-step lipid-modification mechanism — myristoylation at Gly2 for membrane association and palmitoylation at Cys5 for plasma membrane targeting — explaining how the enzyme is positioned to regulate local cyclic nucleotide pools at synapses.

   Evidence Mutagenesis of acylation sites, [³H]myristate incorporation, fluorescence microscopy in HEK293/PC12 cells and hippocampal neurons, subcellular fractionation

   PMID:19632989

   Open questions at the time

   • Whether palmitoylation is dynamically regulated to control PDE2A redistribution was not tested
   • Mechanism applies to PDE2A3; membrane targeting of PDE2A1 and PDE2A2 was not addressed
4. 2013 Medium

   Pharmacological dissection in gastric mucous cells demonstrated that PDE2A acts as a cGMP-dependent brake on cAMP accumulation, restraining PKA-driven Ca²⁺-regulated exocytosis — extending the enzyme's cGMP-to-cAMP cross-talk function beyond neurons.

   Evidence Selective PDE2 inhibitor BAY-60-7550, cAMP/cGMP measurements, exocytosis frequency assays in antral mucosae

   PMID:23449671

   Open questions at the time

   • Genetic confirmation of PDE2A identity (vs. other PDE2 family members) in this tissue was not provided
   • Physiological source of cGMP stimulating PDE2A in vivo was not identified
5. 2015 Medium

   Electrophysiological evidence in hippocampal slices showed that PDE2A inhibition alters paired-pulse facilitation only when both adenylyl and guanylyl cyclases are co-stimulated, establishing that PDE2A functions presynaptically to integrate cGMP signals into cAMP-dependent neurotransmitter release.

   Evidence Paired-pulse facilitation in acute rat hippocampal slices with selective PDE2A inhibitor PF-999 and pharmacological cyclase stimulation

   PMID:26178667

   Open questions at the time

   • Identity of the presynaptic cGMP source (NO-sGC vs. natriuretic peptide-pGC) was not determined
   • Effect on specific neurotransmitter release (glutamate vs. GABA) was not resolved
6. 2018 High

   Discovery of a homozygous GAF-B domain mutation (p.Asp480Gly) causing early-onset hereditary chorea linked PDE2A enzymatic activity to striatal circuit integrity, providing the first direct genetic evidence that PDE2A loss-of-function causes human neurological disease.

   Evidence Whole-exome sequencing in affected family, enzymatic activity assay of recombinant Asp480Gly mutant

   PMID:29392776

   Open questions at the time

   • Number of families carrying PDE2A mutations was limited
   • Mechanism by which reduced PDE2A activity specifically disrupts striatal (chorea-relevant) versus other circuits was not defined
7. 2020 Medium

   PDE2A knockout mouse lethality traced to hepatoblast apoptosis via a cAMP→ICER→Bcl2 axis revealed an essential developmental role outside the nervous system, demonstrating that PDE2A-dependent cAMP restraint is required for fetal liver organogenesis and hematopoietic niche maintenance.

   Evidence PDE2A knockout mouse, cAMP measurement, Western blot for ICER and Bcl2, apoptosis assays, in vitro hematopoietic differentiation

   PMID:32326334

   Open questions at the time

   • Whether the hepatic phenotype is cell-autonomous was not shown by conditional knockout
   • Contribution of cGMP elevation versus cAMP elevation to the lethality was not separated
8. 2023 Medium

   Isoform-specific CRISPR knockouts in cardiomyocytes showed that PDE2A2 is the sole neonatal isoform while adults express all three (A1, A2, A3), each with distinct contributions to cAMP compartmentalization, revealing developmental isoform switching and functional non-redundancy.

   Evidence CRISPR/Cas9 isoform-specific knockout via adenovirus in primary rat cardiomyocytes, FRET-based cAMP biosensors

   PMID:37296663

   Open questions at the time

   • In vivo cardiac phenotype of isoform-specific loss was not assessed
   • Subcellular targeting determinants distinguishing PDE2A1 from PDE2A2 in cardiomyocytes were not defined
9. 2024 Medium

   Haploinsufficient mice revealed that 50% reduction in PDE2A disproportionately elevates cGMP over cAMP in striatum, with compensatory nNOS upregulation, indicating a homeostatic nNOS/NO/cGMP feedback loop that partially buffers cAMP when PDE2A activity is reduced.

   Evidence PDE2A+/− mice, cyclic nucleotide quantification, Western blot, immunohistochemistry for nNOS, behavioral testing

   PMID:39733958

   Open questions at the time

   • Whether nNOS upregulation is transcriptional or post-translational was not determined
   • Behavioral consequences of haploinsufficiency were mild; relevance to human heterozygous carriers is unclear
10. 2025 Medium

    Live biosensor imaging in a Parkinson's disease model demonstrated that NO-driven cGMP elevation activates PDE2A to suppress D1-receptor-driven cAMP/PKA hypersensitivity in dopamine-depleted striatal neurons, positioning PDE2A as a therapeutic target for L-DOPA-induced dyskinesia.

    Evidence Genetically encoded cAMP/PKA biosensors in striatal neurons, PDE2A pharmacological inhibition, 6-OHDA mouse model

    PMID:40412662

    Open questions at the time

    • Whether PDE2A activation can prevent dyskinesia in vivo was not tested
    • Direct measurement of PDE2A protein levels or activity changes after dopamine depletion was not performed

• Key unresolved questions include the full-length structure of PDE2A with GAF domains in both cGMP-free and cGMP-bound states, the identity of physiological cGMP sources driving PDE2A activation at specific synapses, and the mechanism by which PDE2A loss selectively produces striatal pathology despite broad expression.
• No full-length PDE2A structure with GAF domains resolved
• Physiological cGMP source at individual synapses not identified
• Cell-type-specific conditional knockouts in brain not reported